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Grading of prostate cancer: a work in progress
Grading of prostate cancer has evolved substantially
over time, not least because of major changes in diag-
nostic approach and concomitant shifts from late- to
early-stage detection since the adoption of PSA test-
ing from the late 1980s. After the conception of the
architecture-based nine-tier Gleason grading system
more than 50 years ago, several changes were made
in order to increase its prognostic impact, to reduce
interobserver variation and to improve concordance
between prostate needle biopsy and radical prostatec-
tomy grading. This eventually resulted in the current
five-tier grading system, with a much more detailed
description of the individual architectural patterns
constituting the remaining three Gleason patterns
(i.e. grades 3–5). Nevertheless, there is room for
improvement. For instance, distinction of common
grade 4 subpatterns such as ill-formed and fused
glands from the grade 3 pattern is challenging, blur-
ring the division between low-risk patients who could
be eligible for deferred therapy and those who need
curative therapy. The last few years have witnessed
the publication of several studies on the prognostic
impact of individual architectural subpatterns show-
ing that, in particular, the cribriform pattern
exceeded the prognostic impact of other grade 4 sub-
patterns. This review provides an overview of the
changes in prostate cancer grading over time and
provides a thorough description of the various Glea-
son subpatterns, the current evidence of their prog-
nostic impact and areas of contention. Potential
practical ways for improvements of the current grad-
ing system are also put forward.
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Introduction
In order for a grading system to be successful, three
criteria must be met: (i) prognostic ability exceeding
clinical parameters, (ii) reproducibility among pathol-
ogists and (iii) grading results on random biopsies suf-
ficiently representative for the entire cancer.1 Despite
the notable interobserver variation among patholo-
gists, histopathological grading of prostate cancer
remains the strongest prognosticator of disease recur-
rence and death, and the main stratification tool of
patients for their various treatment options. Several
grading systems were used over time, but since the
late 1990s the Gleason grading system, conceived in
1966, was gradually adopted worldwide, replacing a
multitude of competing grading systems.2 The cap-
ture of the complex architectural heterogeneity of
prostate cancers in a single drawing by Gleason
proved to be a very attractive concept for patholo-
gists. Actually, to some extent the combining of the
most dominant architectural patterns in one score
seems to have overcome the heterogeneity issue
which now may limit the utility of molecular–genetic
biomarkers.3
Updates of Gleason grading were largely based on
expert rather than evidence-based opinion.4 How-
ever, in more recent years several studies have
focused on the prognostic impact of individual pros-
tate cancer growth patterns.5–8 Further, interob-
server variation for individual Gleason grade
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(sub)patterns was studied in greater detail.9–11
Employing molecular–genetic analysis of microdis-
sected samples as a tool to gain insight into pros-
tate cancer evolution shed some light on the clonal
evolution of prostate cancer.12
After a description of historical aspects of prostate
cancer grading, this review will provide an extensive
overview of the various subpatterns constituting the
individual Gleason grades. The main objectives are:
(i) to summarise the current evidence for prognostic
impact of each of these Gleason grade subpatterns,
(ii) to point out areas where such data are lacking
and (iii) discuss potential implications of recent
insights in prostate cancer grading for future
improvement.
History of Prostate Cancer Grading
Initially, prostate cancers were mainly graded using
the universal four-tiered Broders system published in
1926.13 This grading system was based on low
microscopic power evaluation of the percentage of
glandular differentiation. A detailed study published
in the first decade of the 20th century had already
mentioned the wide variability in appearance of pros-
tate cancer, recognising several histological growth
patterns, such as acinar, scirrhous and solid.14 This
morphological heterogeneity challenges the develop-
ment of a grading system in determining which histo-
logical features should be taken into account to
assign a grade. Ahead of his time, in 1966 Donald
Gleason developed a histological classification specifi-
cally for prostate cancer, which was entirely based on
the various architectural patterns as depicted in his
famous drawing.15 He distinguished five basic archi-
tectural patterns, numbered grades 1–5. Higher
grades were considered to reflect more aggressive
behaviour. Because the majority of prostate cancers
showed more than one type of growth pattern, he
assigned two patterns to each case in the order of
predominance, adding the two most dominant pat-
terns or grades to a single Gleason score or doubling
the pattern number if only one pattern was present,
resulting in a nine-tier grading system. After valida-
tion of the prognostic relevance of the Gleason grad-
ing system in 197416 it slowly gained worldwide
acceptance,17 and is now the recommended grading
system for prostate cancer.
Next to grading systems requiring a low-power
evaluation of the glandular architecture the Mostofi
grading system,18 adopted by the World Health
Organisation (WHO) in 1980,19 also included the
degree of cytonuclear atypia in the worst tumour
area as a grading criterion in addition to the percent-
age glandular differentiation as originally defined by
the Broders system. Others1,20 refined this system by
a more detailed description of the glandular patterns,
including the distinctive cribriform pattern. The four-
tiered MD Anderson grading system, developed at
around the same time, was entirely based on the per-
centage glandular differentiation, but the cribriform
pattern was specifically assigned to the ‘grade 2’ cate-
gory.21 Several grading systems were simultaneously
in routine use until approximately 2000. This was an
unsatisfactory situation, as it limited the comparison
of different patient series and adoption of a standard
risk classification.
Although several studies demonstrated the prog-
nostic potential of cytonuclear grading,20,22,23 the
lack of interobserver agreement and its sensitivity to
variations in pathology processing reduced its routine
applicability. Interestingly, a recent paper using an
eye-tracking device revealed that nuclear grading
was subconsciously biased by the carcinoma architec-
ture.24 This may explain why the cytonuclear atypia-
based now obsolete Mostofi (WHO) grading and the
architecture-based Gleason grading show a strong
correlation,25 despite their fundamental conceptual
differences.
Modifications were made to the Gleason grading
system, a major one in 20054 and another in
201426 during two International Society of Urological
Pathologists (ISUP) consensus conferences. Originally,
Gleason did not describe and specifically grade ill-
formed glands. During the ISUP consensus conference
in 2005, the ill-formed pattern was added to Gleason
grade 4. Consequently, from then on Gleason grade 3
only comprised well-delineated malignant glands.
This, and the recommendation for prostate biopsies to
include any amount of grades 4 or 5 carcinoma in
the Gleason score, even if less than 5% of the carci-
noma extent, led to a substantial grade inflation.27 In
2005 it was also agreed that large cribriform glands
should be diagnosed as a Gleason grade 4, while
small cribriform glands could still be assigned a Glea-
son grade 3. Because of the poor interobserver repro-
ducibility on diagnosing cribriform grade 3 glands,28
it was decided during the 2014 ISUP consensus con-
ference to consider any cribriform pattern as a Glea-
son grade 4. For many years, grading glomeruloid
architecture was also controversial. Its frequent asso-
ciation with other grade 4 patterns, including cribri-
form architecture,29 led in 2014 to its inclusion as a
Gleason grade 4. Some studies reported an improve-
ment in concordance between biopsy and prostatec-
tomy Gleason score as well as observer
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reproducibility after the 2005 modification, while
others failed to show such an improvement.9,30 The
latter could be attributed in part to the large number
of possible Gleason scores.
A lowest Gleason score of 6 was perceived as an
anomaly, increasing unnecessary anxiety of men
diagnosed with this low-risk prostate cancer and
who were now offered deferred treatment. By 2000
Gleason patterns 1 and 2, typical of low-grade tran-
sition zone carcinomas as encountered in transure-
thral resections, were hardly reported any more in
biopsies31 and Berney suggested in 2007 that the
lower scores should be removed from the Gleason
system.32 Several groups noted that the proportion
of high-grade cancer might be more prognostic than
the Gleason score per se.33–35 Subsequently, Stark
et al. demonstrated convincingly that separation of
Gleason score 7 into two subsets, that is, those with
a predominant grade 3 component [i.e. 7 (3 + 4)]
and those with a predominant grade 4 component
[i.e. 7 (4 + 3)] strongly improved its prognostic
impact.36 Over time, various combinations of Glea-
son score condensations were shown to be instru-
mental in the prediction of recurrent disease.37 In
2013 Epstein and Partin updated their pathological
staging nomogram with tumours grouped as per
Gleason scores 6, 7 (3 + 4), 7 (4 + 3), 8 and 9–
10.38 This five-tier ‘prognostic grade grouping’39
was subsequently endorsed by the ISUP in 2014 and
recommended by the WHO and the American Joint
Committee on Cancer (AJCC) tumour–node–metasta-
sis (TNM) system:40,41 Gleason scores ≤6 were com-
pressed into ISUP grade (group) 1 and Gleason
scores 9–10 into ISUP grade (group) 5, whereas
Gleason score 7 was expanded to ISUP grade (group)
2, i.e. 7 (3 + 4) and ISUP grade (group) 3, i.e. 7
(4 + 3). Independent validation on historical data
sets of this ‘renumbering’ of the Gleason score
demonstrated its prognostic impact in biopsies and
prostatectomies.42
ISUP 2014 Grading of Prostate Cancer
Henceforth, for simplicity we will refer to the individ-
ual grades of the grade group system as ISUP
grades,43 a terminology now also adopted by the
European Association of Urology (EAU) guideline
committee of prostate cancer.44 An important advan-
tage of this grading system is that it now ranges from
1 to 5. ISUP grade 1 carcinoma terminology may
help acceptance of active surveillance, as it may be
perceived as less ominous than Gleason score 6
(3 + 3) carcinoma. Another advantage is that the
2014 modification codifies the previously established
substantial prognostic difference between Gleason
scores 7 (3 + 4) and 7 (4 + 3). Unsurprisingly, com-
parison with a four-tier Gleason score grouping (i.e.
Gleason scores 6, 7, 8, 9–10) demonstrated the supe-
rior prognostic impact of the five-tiered ISUP grading
for both clinical and pathological outcome parameters
after prostatectomy.45,46 Commonly used clinical risk
stratification systems such as D’Amico consider Glea-
son score 7 as a major criterion for intermediate-risk
prostate cancer. They may now need to adapt their
risk stratification based on ISUP grades. Indeed, the
current National Comprehensive Cancer Network
(NCCN) guidelines on prostate cancer distinguishes
between favourable and unfavourable intermediate
risk based, among others, on the distinction between
ISUP grades 2 and 3.47 Similarly, the Cancer of the
Prostate Risk Assessment (CAPRA) score for biopsies
and prostatectomy specimens distinguishes ISUP
grades 2 and 3.48 A potential disadvantage of the
ISUP 2014 grading system might be the loss of the
linkage with the underlying heterogeneity in carci-
noma architecture. For instance, differences between
Gleason scores 3 + 5 and 5 + 3 versus 4 + 4 will no
longer be apparent, as they will all be reported as
ISUP grade 4.37
It is now recommended that the aggregated ISUP
grade should be reported for each individually
labelled biopsy site.49 If multiple cores of one biopsy
site contain carcinoma, it is optional to report the
grade for each core. Further, a global Gleason score is
generally reported taking into account the grade pat-
terns of the carcinoma foci encountered in all cores.
Although it may seem counterintuitive, three recent
studies showed that the global Gleason score outper-
formed the ‘worst’ Gleason score with regard to
pathological features in corresponding prostatectomy
specimens.50–52
Grading of prostatectomy specimens follows slightly
different rules compared to biopsy grading: if no
clearly spatially separate carcinoma foci with dis-
parate grade are detected a ‘global’ ISUP grade is
reported. If a predominant Gleason grade 3 carci-
noma is identified with a minor (i.e. <5%) grade 4,
the minor component is not accounted for in the
ISUP grade, but recorded as a minor component. If
Gleason grades 3 and 4 are the two dominant pat-
terns and a grade 5 component comprises less than
5% of the carcinoma area, most would not include
the grade 5 in the ISUP grade, but report it as minor
grade 5 component. If, however, the grade 5 compo-
nent represented the third most common pattern,
while exceeding 5% of the carcinoma area, many
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pathologists would include the grade 5 component in
the ISUP grade.
D E S C R I P T I O N O F I S U P 2 0 1 4 G L E A S O N G R A D E 3
P A T T E R N S
Gleason grade 3 pattern is defined by well-differen-
tiated glands, separated from each other by stroma. A
few subpatterns can be distinguished, based on the
density of neoplastic glands and on architectural vari-
ations (Table 1). The density of the neoplastic glands
is defined by both the amount of intervening stroma
and presence of intervening benign glands. A dense
pattern is characterised by glands close to each other
with a minimum amount of intervening stroma (Fig-
ure 1A). These grade 3 carcinomas can form prostate
nodules, and if sufficiently large they are visible at
imaging.53 A ‘sparse’ Gleason grade 3 pattern is char-
acterised by carcinoma glands separated by benign
prostatic glandular tissue, including stroma, and can
be defined arbitrarily as comprising less than 50% of
the tumour area (Figure 1B). As a consequence,
sparse Gleason grade 3 pattern remains invisible in
imaging.54 Rarely, a desmoplastic stroma may be pre-
sent in a grade 3 carcinoma (Figure 1C), thought to
portend an unfavourable prognosis.8 The usual archi-
tecture of grade 3 carcinoma glands is tubular of vari-
able size, but sometimes an atrophic,55 branching,26
pseudohyperplastic,56,57 PIN-like,58 mucinous or col-
lagenous micronodular (also termed mucinous fibro-
plasia)59 architecture may be seen (Table 1,
Figure 1D–H). PIN-like58 or PIN-like ductal60 adeno-
carcinoma is characterised by several close by, often
cystically dilated, glands architecturally resembling
high-grade prostatic intra-epithelial neoplasia, lined
by pseudostratified columnar epithelium with cytonu-
clear atypia, while entirely lacking a basal cell lining.
Particularly when limited in extent, these lesions may
be difficult to distinguish from high-grade PIN. It was
agreed at the ISUP 2005 consensus meeting4 that
mucinous carcinomas (Figure 1F) would be graded on
the basis of its glandular architecture. A recent paper
on carcinomas with a mucinous component noted
that they were often high-grade, but confirmed that
their prognosis depends on the underlying Gleason
architecture.61 Similarly, it was concluded that the
presence of large cytoplasmic vacuoles should not
change the Gleason grade in an architecturally Glea-
son grade 3 carcinoma.
The biological behaviour of pure Gleason grade 3
pattern is well established: it may behave locally
aggressively, but at the time of prostatectomy rarely,
if ever, gives rise to metastatic disease.62,63
Importantly, it is not known how frequently Gleason
pattern 3 may transform into a more aggressive pros-
tate cancer, although some have estimated that an
approximately 20% grade transformation may occur
Table 1. Summary of Gleason patterns and sub-patterns*
Grade 3




Sub-patterns based on architecture
Atrophic
Branching





Sub-patterns based on architecture
Ill-formed
Abortive
Small- and large fused
Glomeruloid
Cribriform (small and large)
Papillary
Ductal adenocarcinoma
Non-ductal (including PIN-like cystic)
Grade 5








*Definitions provided in the text.
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over time.64,65 A deep sequencing study revealed that
a proportion of Gleason grade 3 pattern carcinomas
are monoclonal, whereas a subset is composed of
multiple subclones. This may imply that the latter are
subject to genetic evolutionary changes.66
D E S C R I P T I O N O F I S U P 2 0 1 4 G L E A S O N G R A D E 4
P A T T E R N S
The 2014 ISUP consensus meeting established that
Gleason pattern 4 comprises ill-formed or poorly
formed, (small and large) fused glands as well as
glomeruloid and cribriform architecture (Table 1, Fig-
ure 2A–D). The overall prevalence of Gleason grade 4
subpatterns in biopsies of a prostate-specific antigen
(PSA)-screened population was: fused 75%, ill-defined
64%, cribriform 48% and glomeruloid 25%.6 In
prostatectomy series, among the carcinomas with
grade 4 component the frequency of fused glands was
38%, ill-formed glands 40% and glomeruloid 21%,7
while in various publications the prevalence of cribri-
form architecture ranged in prostatectomy specimens
Figure 1. Gamut of Gleason grade 3 adenocarcinoma, including (A) densely packed medium-sized well-delineated tubules, typical of transi-
tion zone carcinoma, (B) ‘sparse’ carcinoma consisting of scattered acinar and tubular structures (arrows) widely separated from each other
by intervening normal fibromuscular stroma and benign glands, (C) ‘stromogenic’ carcinoma showing well-delineated small- to medium-sized
glands within a desmoplastic stroma, (D) atrophic variant carcinoma consisting of acini lined by flattened epithelial cells, (E) branching pat-
tern carcinoma comprised of distinct medium-sized glandular structures with branching outpouchings, not to be confused with fusing of
glands, (F) pseudohyperplastic pattern adenocarcinoma with tumorous glands mirroring the architecture of normal benign glands, (G) PIN-
like adenocarcinoma, constituted of large-sized glands lined by columnar neoplastic cells, lacking a layer of basal cells demonstrated by
immunostaining, (H) miconodular collagenous nodule with entrapped acinar carcinoma cells with complex architecture and (I) mucinous
carcinoma with distinct small-sized neoplastic acini within extracellular mucin.
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between 30 and 55%.5,7,67 A few authors noted that
particularly in Gleason grade 4 pattern the stroma
component could vary strongly from normal to
desmoplastic, carrying independent prognostic infor-
mation.68,69
Ill-formed and fused glands
Ill- or poorly formed glands are defined as small-sized
discrete glands with no or rare lumens, elongated
compressed or angulated glands and elongated nests
visible at low power, while tangential sectioning of
grade 3 glands cannot account for this histology.4,11
Included in this definition of ill-formed glands are the
so-called ‘abortive’ glands, larger discrete elongated
nests or strands, lacking a lumen (Figure 2E). Fused
glands can be small- or large-sized (Figure 2F) and
display multiple merged glandular strands and nests
with lumen formation (Figure 2B). They are often
combined with ill-formed glands4 and may therefore
be difficult to separate. Some fused glands with more
complex architecture, labelled complex-fused glands
(Figure 2G), may have a pseudo-cribriform appear-
ance.10
At the time of their codification as a grade 4 pattern
in 2005, no outcome data were available to confirm
their unfavourable prognosis compared to Gleason
grade 3 pattern. A prostatectomy study by Dong et al.
demonstrated that patients upgraded due to the 2005
modification to Gleason score 7 (due mainly to pres-
ence of ill-formed glands, but also due to cribriform
Figure 2. Depiction of grade 4 subpatterns: (A) haphazardly distributed poorly formed very small-sized distinct glands showing some lumen-
formation, (B) fused small-sized lumen-containing glands in a retiform pattern, (C) focus of glomeruloid structures within small- to medium-
sized distinct glands, (D) expansile rounded tumour area with cribriform pattern lacking intervening stroma or capillaries, (E) abortive glands
consisting of structures with glandular shape, but lacking a lumen, to be distinguished from solid pattern grade 5 carcinoma, (F) large-sized
glands which merge together, constituting the large-fused pattern, (G) complex fused glands with irregular cribriform area, but with inter-
vening stroma and capillaries, (H) large-sized glands with glomeruloid features showing a cribriform pattern, adjacent to small-sized
glomeruloid glands and (I) papillary pattern lined by columnar tumour cells reminiscent of ductal adenocarcinoma.
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pattern) were at intermediate risk for biochemical pro-
gression and metastasis compared to those with ISUP
2005 modified Gleason score 3 + 3 = 6 and patients
with classical Gleason score 3 + 4 = 7.67 Conversely,
Delahunt did not find a significant difference between
pre-ISUP 2005 and ISUP 2005 modified Gleason
scores 6 and 7 carcinomas in biopsies.70 Some
authors demonstrated in a large prostatectomy cohort
that increased proportions of ill-formed glands in a
carcinoma would gradually increase the risk of carci-
noma recurrence after prostatectomy.7,8 Kweldam
et al.63 revised the grading of a set of 796 Gleason
score ≤7 (3 + 4) biopsies using the ISUP 2014 criteria
and distinguished those with and without cribriform
pattern. Patients who had biopsy ≤ISUP grade 2 with-
out cribriform pattern (mainly ill-formed or fused
glands) had a similar biochemical recurrence rate
after prostatectomy to men with ISUP grade 1. The
above studies imply that the inclusion in the ISUP
grade of any amount of grade 4, in particular of ill-
formed and fused glands as per the ISUP 2005 modifi-
cation, needs further optimisation.
Glomeruloid architecture
The glomeruloid pattern is defined as dilated cancer
glands of variable size, with cribriform cancer pro-
truding into the lumen yet not attaching to the other
side of the gland wall, superficially resembling a
glomerulus.26 Because of its morphological resem-
blance to the cribriform pattern, particularly when
larger-sized (Figure 2H), some suggested that a
glomeruloid pattern might represent the precursor for
a cribriform pattern.29 A few subsequent studies
showed that a glomeruloid pattern was actually asso-
ciated with reduced risk of biochemical recurrence
after radical prostatectomy,6,7 but compared to a pure
grade 3 glomeruloid pattern was more unfavourable,
justifying its inclusion in the grade 4 category.7
Cribriform architecture
Cribriform carcinoma (Figure 2D) can be defined as an
expansile area of carcinoma cells without intervening
stroma or vasculature and with a diameter of at least
an average-sized (diameter approximately 200 lm)
benign gland and with multiple punched-out lumina,71
irrespective of its delineation. Earlier studies reported
that proliferative activity was highest in this subpat-
tern.72,73 In 2011, Iczkowski et al. were the first to
report that prostate cancer patients with cribriform
growth (although also including the glomeruloid pat-
tern) had a worse biochemical-recurrence-free survival
than those with ‘poorly formed glands’.5 Subsequently,
the adverse prognostic value of prostate cancers with a
cribriform pattern was validated in several biopsy and
prostatectomy studies, using different patient groups
and outcome measures, including biochemical recur-
rence, metastasis and disease-specific death.74 Notably,
among Gleason score 8 cancers, the question of
whether the highest Gleason grade was 3 + 5 versus
4 + 4 proved only mildly predictive of recurrence. How-
ever, the presence of cribriform cancer dichotomised
cancer-specific survival in Gleason 8 cancer,75 corrobo-
rating another large biopsy-based study showing that
across all Gleason score >6 carcinomas, the presence of
a cribriform pattern predicted metastatic disease and
death of disease.63 Together, these studies indicate that
cribriform architecture in prostate cancer carries a
much higher risk of disease progression compared to
the other Gleason grade 4 patterns.76 Some papers also
showed that the presence of cribriform architecture cor-
relates strongly with the percentage of grade 4 carci-
noma in biopsies6 and prostatectomy specimens.7
Papillary/ductal adenocarcinoma architecture
Papillary architecture (Figures 2I and 3) is not men-
tioned separately in the ISUP 2005/2014 grading
system, but was included in the earlier descriptions of
the Gleason grade 4 patterns. Papillary formations
are characteristic for ductal adenocarcinoma when
lined by tall columnar cells with elongated nuclei and
showing pseudostratification (Figure 3A), but these
structures can also be encountered in the setting of
pseudohyperplastic variant carcinoma (Figure 3B),
intraductal carcinoma, cystic PIN-like ductal adeno-
carcinoma (Figure 3C)60 and in other Gleason grade
4 carcinomas lacking tall columnar cells typical of
ductal adenocarcinoma (Figure 3D).77,78
D E S C R I P T I O N O F I S U P 2 0 1 4 G L E A S O N G R A D E 5
P A T T E R N S
Gleason grade 5 pattern represents carcinoma areas
detectable at low power (at most, 910 objective)
which essentially lack glandular features such as
lumen formation or glandular contours (Figure 4A–
F). Its frequency in larger biopsy series is approxi-
mately 5%.79,80 A few main patterns can be distin-
guished (Table 1), including comedonecrosis, single-
file/infiltrating cords and solid pattern.4,81 The pres-
ence of comedonecrosis in a single carcinoma gland
(focal comedonecrosis) is deemed sufficient for Glea-
son grade 5.4 Signet-ring-like cells, if arranged as sin-
gle cells, solid larger nests (Figure 4F) or single files
are also considered as Gleason 5 pattern. Single-file/
infiltrating cords without lumen formation and single
cells are the most frequent and comedocarcinoma the
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least frequent grade 5 pattern in biopsies.82 Interob-
server agreement is, however, lowest in biopsies for
the patterns of infiltrating cords and single cells and
highest for comedocarcinoma. The rare Paneth cell-
like differentiation in prostate cancer may show a
nested or cord-like architecture, but they seem to
have a favourable prognosis and therefore should be
graded as 3, instead of 4 or 5.83 Grade 5 pattern ade-
nocarcinoma should be distinguished mainly on mor-
phological grounds from poorly differentiated
neuroendocrine carcinoma, as the latter show a
much higher nucleus/cytoplasm ratio, with hyper-
chromasia of nuclei and nuclear moulding, while
mitotic activity is very high. Immunostaining is an
ancillary tool, as poorly differentiated neuroendocrine
carcinomas often express one or more neuroen-
docrine markers, such as chromogranin A and synap-
tophysin, and have a MIB-1 score of more than 50%,
while mainly lacking expression of androgen receptor
and PSA.
P R O B L E M A T I C A R E A S
Distinction of grade 3 versus 4 patterns
Due to ‘grade inflation’ as a consequence of the deci-
sion at the 2005 modification of the Gleason grading
to incorporate any amount of Gleason grade 4 pattern
in the Gleason score of a biopsy,27 distinction of
grades 3 and 4 has become even more pertinent. Dis-
crepancies mainly arise from the distinction of grade 3
from ill-formed (Figure 5A–C) and small-fused glands
(Figure 5D). Downgrading a biopsy Gleason score 7 to
a Gleason score 6 at prostatectomy could be attributed
in most cases to these two patterns in the biopsy.84
The sizes of well-defined Gleason grade 3 glands range
from large-size, difficult to separate from benign
glands, to ever smaller-sized glands, and there is no
abrupt distinction from ill-formed glands (Figure 5A).
Based on an interobserver variation study, Zhou et al.
suggested that a minimum of 10 ‘ill-formed’ glands
constituting a separate tumour area in an otherwise
Gleason grade 3 pattern tumour would be required to
assign a grade 4 (Figure 5B,C). Ill-formed glands
intermingled with bona-fide pattern 3 glands should
not, in their view, lead to an upgrading of the
biopsy.11 Further studies on the three-dimensional
architecture and outcome of non-cribriform Gleason
score 3 + 4 = 7 compared to Gleason score 3 + 3 = 6
prostate cancer might reveal whether distinction of ill-
formed Gleason pattern 4 from Gleason pattern 3 is
objectively feasible based on specific differences85 and
are of clinical relevance.86
Small-fused glands may not only be difficult to distin-
guish from ill-formed glands, but also from closely
packed Gleason grade 3 glands (Figure 5D). The pres-
ence of subtle intervening wisps of stroma separating
A B
DC
Figure 3. Composite of prostatic adenocarcinomas with papillary architecture: (A) classical ductal (‘endometrioid’) carcinoma, characterised
by papillary formations, lined by tall columnar neoplastic cells, (B) papillary formations lined by tumour cells resembling benign prostate
glandular luminal cells in a pseudohyperplastic variant carcinoma, (C,D) papillary formations protruding into larger cystic spaces and lined
by columnar luminal cells with round (basal) nuclei (C) or with apical nuclei (D) distinct from the ductal adenocarcinoma as shown in (A).
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each acinar structure is deemed sufficient to assign a
Gleason grade 3. Further, the examination of multiple
levels in a biopsy may help to distinguish tangentially
cut pattern 3 and fused glands. We would suggest that,
as a rule of thumb, manifestation as pattern 3 in one
level is sufficient to abstain from grade 4 diagnosis at
biopsy, even if in other levels a fused pattern seems to
be present. Uncommonly, well-defined carcinoma aci-
nar structures may be embedded in a collageneous
(desmoplastic) stroma (Figure 1C). McKenney et al.8
demonstrated its more aggressive behaviour, which
would suggest that this variant may actually constitute
a grade 4 pattern.
Pseudohyperplastic variant prostatic adenocarci-
noma56,57 is categorised as Gleason pattern 3, but due
to its complex architecture it may mimic a fused gland
or papillary pattern. Sometimes, immunostaining is
required for distinction from high grade PIN (Figure 1F).
More rarely, well-demarcated separate acini com-
posed of tumour cells with severe cytonuclear atypia
and a lumen filled with necrotic or eosinophilic mate-
rial may occur.26 They would fulfil the criteria of a
Gleason grade 3 pattern, but their cytonuclear atypia
suggests otherwise (Figure 5E). ‘Abortive’ glands may
also be confused with a grade 3 pattern, but can
easily be distinguished by the absence of glandular
lumina in multiple levels. Distinction of grade 3 and
glomeruloid architecture should rarely cause
confusion. Only distinction of telescoping in a grade 3
gland from a true glomeruloid pattern may occasion-
ally cause uncertainty. Cribriform pattern and intra-
ductal carcinoma are unlikely to be confused with a
grade 3 pattern. Carcinomas with extracellular mucin
and/or fibroplasia may manifest both as grade 3 or
grade 4, dependent upon the complexity of the glan-
dular structures. More recently, some authors sug-
gested that mucinous carcinoma would behave in an
indolent manner, just like grade 3, even if the glan-
dular architecture would be more in keeping with
grade 4 fused glands.8 Therefore, a conservative
approach with respect to grading of mucinous variant
carcinoma is recommended.26 The mucinous features
often seem to merge with micronodular collagenous
(mucinous fibroplasia) carcinoma areas, which may
show a more complex glandular features (Figure 1H).
The latter are not associated with aggressive carci-
noma, and their behaviour was reported to be similar
to grade 3 pattern carcinoma.59 A more recent paper
observed, however, that this fibronodular pattern was
frequently associated with cribriform pattern, but out-
come data were not provided.87
Distinction within grade 4 architectural patterns
In a few interobserver studies, the distinction between
the main Gleason grade 4 subpatterns was anal-
ysed.9,10,28 Ill-formed and small-fused glandular
Figure 4. Most common grade 5 patterns, such as (A) comedocarcinoma, showing a necrotic central plug surrounded by fused glands, (B)
single cells with vacuolisation with haphazard distribution between benign glands, (C) single file of tumour cells, lacking lumina, embedded
in dense stroma, (D) smaller solid areas (upper right) with some acinar (pseudo-rosetting) nuclear arrangement, but lacking lumen forma-
tion, (E) larger sheet of poorly differentiated tumour cells and (F) solid area of cells with signet ring-like appearance.
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patterns are most difficult to separate, but they may
be similar in clinical significance. To a lesser extent,
glomeruloid and cribriform patterns were subject to
interobserver disagreement. Glomeruloid architecture
may vary in size, and in particular larger-sized
glomeruloid glands (Figure 2H) were considered by
several pathologists as cribriform. Although at the
2005 Gleason grading modification small and large
cribriforms were separated, based on the number of
lumina (= <6 or >6, respectively), this distinction was
abolished at the 2014 ISUP consensus meeting.
For the uncommon ‘complex-fused’ glands pattern
(Figure 2G), pathologists were often split between
fused and cribriform,10 while its additional prognostic
impact remains unclear.
Distinction of grades 4 and 5 architectural patterns
It has been common practice to be very conservative
when assigning a Gleason grade 5. Most frequently,
disagreement may arise when single cells or strands
without apparent lumen formation are present, lead-
ing to a differential diagnosis of ill-formed glands ver-
sus single-file types of grade 5 carcinoma. An
interobserver variation study noted that: ‘rare individ-
ual cells, strands, or nests identified only at less than
940 lens magnification were considered sufficient to
diagnose Gleason pattern 5 on needle biopsy by 17%
of pathologists, whereas 83% required clusters of
such structures seen at lower than 940 magnifica-
tion. The Gleason pattern 5 identified by occasional
observers in some cases proved to be minute
Figure 5. Architectural patterns which may be challenging for grading: (A) well-defined grade 3 medium-sized glands transitioning to and
intermingling with increasingly smaller-sized glands, but still considered as grade 3, contrasting with (B) medium-sized grade 3 glands with
an abrupt transition to a cluster of ill-formed (grade 4) glands and (C) medium-sized well-described grade 3 glands slowly transitioning into
a larger field (>10 structures) of ill-formed (grade 4) glands. In (D) small-sized closely packed circumscribed glands surrounded by thin wisps
of stroma, most consistent with grade 3 glands, (E) well-circumscribed pale glands with flocculated eosinophilic lumen content and consider-
able cytonuclear atypia (compared to gland on the right side) and (F) pseudo-rosetting pattern in an otherwise solid carcinoma field in a
biopsy considered as grade 5 pattern at the ISUP 2014 consensus meeting.
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components rather than cohesive areas and should
be overlooked according to the vast majority of obser-
vers’.9
A grade 5 area single-file pattern should, in our
opinion, be manifest as a morphologically distinct
tumour area at low power. Intermingling of ill-formed
glands with minimal lumen formation, identified at
any level of sectioning, should exclude a grade 5
diagnosis. A solid pattern carcinoma may sometimes
merge with a cribriform pattern, giving rise to solid
areas with so-called rosette-like spaces, defined as aci-
nar structures, lacking a lumen (Figure 5F). At the
2014 ISUP consensus meeting this rosette-like pat-
tern, based on the nuclear arrangement, was
included as a Gleason grade 5 pattern, although no
specific outcome data were provided.26 Its assignment
to grade 5 therefore remains somewhat debatable. It
probably represents part of the gamut of solid well-
demarcated tumour foci ranging from cribriform–
rosette-like solid–comedocarcinoma. Necrosis may be
seen in cribriform areas or in well-described glands.
Irregular (geographic) necrosis is not considered a
feature of grade 5, in contrast to comedonecrosis (Fig-
ure 4A), defined as a central delineated plug of coag-
ulative necrosis. Abortive gland pattern is
uncommon, but should be considered grade 4 due to
its ‘glandular contours’ (Figure 2E). Inclusion of
quantitative criteria would probably improve the
reproducibility among pathologists for some grade 5
patterns, as suggested by Shah et al.82 Thus, restrict-
ing a pattern 5 diagnosis to single cells/single cords if
more than 10, concentrated in a cluster, would result
in fair agreement among pathologists.
Q U A N T I T A T I V E G R A D I N G
Prostatectomy findings of patients with a minimal
amount of Gleason pattern 4 (<5%) in corresponding
prostate biopsies may show a similar pathological stage
and ISUP grade distribution to those with a biopsy ISUP
grade 1.88 In this study, 63% of patients with biopsy
ISUP grade 2 with less than a 5% grade 4 component
were downgraded to ISUP grade 1 at prostatectomy. In
order to mitigate the potential impact of the grade infla-
tion due to the implementation of the 2005 ISUP modifi-
cation on eligibility for active surveillance, the 2014
ISUP consensus/WHO classification of prostate cancer
201641 recommends that percentage Gleason grade 4 is
routinely reported in biopsies with ISUP grades 2 and
3.26 Subsequent studies on quantitative grading showed
the incremental, rather than acute, increase in risk of
biochemical recurrence at higher proportions of the
grade 4 component. It is thought that quantitative
grading might limit the clinical impact of interobserver
variation regarding borderline findings such as tumours
with, for instance, very small Gleason grade 4 fractions
impacting a man’s eligibility for active surveil-
lance.7,51,52 One study reported that interobserver
reproducibility of percent Gleason grades 4 or 5 on pros-
tate biopsies is at least as good as that of Gleason
score.89 A subsequent reproducibility study on percent-
age Gleason grade 4 in prostate biopsies revealed that
when reported in 10% increments, 32% had an exact
match between fellow and expert urological pathologist
and 75% were within a 10% range with a good
(weighted kappa of 0.67) agreement.90 The agreement
for percentage Gleason pattern 4 decreased significantly
only when carcinoma comprised 10% or less of the core.
I N T R A D U C T A L C A R C I N O M A A N D G R A D I N G
Recognition of intraductal carcinoma of the prostate
(IDC-P) as a strong independent prognosticator has
taken several decades since its original discovery: inter-
est in IDC-P as a separate entity was raised in the
1970s and 1980s.91–93 In their landmark paper in
1986, McNeal and Kovi showed the unfavourable
characteristics of associated prostate cancers in prosta-
tectomy specimens harbouring IDC-P. Gleason did not
include IDC-P as a separate pattern in his drawing and
considered IDC-P as cribriform pattern carcinoma or
comedocarcinoma. At that time basal cell staining, a
helpful adjunct to distinguish IDC-P, was not available
and IDC-P was incorporated by default into the Glea-
son grading. Subsequently, IDC-P was tacitly consid-
ered as one of the architectural patterns comprising
the newly adopted (high-grade) prostatic intra-epithe-
lial neoplasia (PIN) label. Because high-grade PIN was
lacking prognostic significance when found in associa-
tion with prostate cancer, awareness of the prognostic
impact of IDC-P waned until O’Brien and Cohen subse-
quently noted its value as an independent unfavour-
able prognosticator, incorporating its presence in a
nomogram used to predict biochemical recurrence
after prostatectomy.94,95 A few subsequent prostatec-
tomy and prostate biopsy studies confirmed the inde-
pendent prognostic value of IDC-P.96,97 The reporting
of IDC-P was discussed at the 2014 ISUP consensus
meeting, and it was decided to report IDC-P separately
if present in isolation and not to include its presence in
the Gleason grading.26 The arguments for this decision
were the analogous situation in other malignancies
and the rare finding of IDC-P in the absence of adeno-
carcinoma (isolated IDC-P) or IDC-P in association
with an ISUP grade 1 prostate cancer as highest
grade.
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Future implications
With the recognition of IDC-P, invasive cribriform car-
cinoma and percentage Gleason patterns 4 and 5 as
separate relevant prognostic parameters, the question
arises as to how these should be incorporated into
pathology reports and clinical decision-making.
Whereas the 2014 ISUP consensus only recommends
reporting of IDC-P if present in isolation, the 2018
EAU guideline on prostate cancer now recommends
separate reporting of intraductal carcinoma when
associated with carcinoma.44,49 In one study it was
shown that combining intraductal and invasive cribri-
form carcinoma on biopsy specimens predicted disease-
specific death more accurately than each separately.63
As invasive and intraductal carcinoma can be difficult
to distinguish without basal cell immunohistochem-
istry, we and others have combined both entities into
one group, labelled CR/IDC or cribriform architecture
(CA).6,63,98 This would overcome the use of additional
stainings for classification of both patterns.
Iczkowski et al. suggested adding ‘C’ to the ISUP
grade, indicating the presence of invasive cribriform or
intraductal carcinoma.74 For instance, ISUP grade 2
prostate cancer with cribriform growth would be classi-
fied as ISUP grade 2C. However, it is still unclear how
the prognostic impact of the ISUP grades would be
mutually related if CR/IDC is incorporated. In a biopsy
cohort it was shown that men with ISUP grade 2 with-
out CR/IDC had similar biochemical recurrence rates
and disease-specific survival to men with ISUP grade
1.6,86 This might imply that one point could be sub-
tracted if CR/IDC is absent in ISUP grades 2–5. There-
fore, ISUP grade 2 without CR/IDC would then be
labelled as modified ISUP grade 1. This would be an
attractive and simple grading scheme, increasing the
number of patients potentially eligible for active surveil-
lance. Future studies should, however, demonstrate
whether such a model is really clinically valid, in partic-
ular also for ISUP grades 3–5.
A few groups have advocated the implementation
of desmoplastic stroma changes in routine reporting.
As yet, lack of independent validation of stromal
changes in prostate biopsies as an independent prog-
nostic parameter and lack of information on its
robustness precludes its routine implementation in
prostate cancer grading.
In a detailed study of 13 261 radical prostatectomy
specimens, Sauter and colleagues developed a ‘inte-
grated quantitative’ Gleason score (‘IQ-Gleason’)
which was based entirely on percentages of Gleason
patterns 4 and 5.99 In this model the absolute quanti-
tative percentages of any Gleason patterns 4 and 5
are summed. If any pattern 5 is seen 10 points are
added, and another 7.5 points if Gleason pattern 5
quantities are larger than 20%. The final score there-
fore ranges from 0 to 117.5. The advantages of this
model are that identical grading rules are applied to
biopsy and surgical specimens and that quantitation
of Gleason patterns 4 and 5 are implemented, with
less interobserver variability than in standard grad-
ing. Conversely, invasive cribriform and intraductal
carcinoma are not accounted for in this model.
For the development of timely nomograms and deci-
sion models it is important to understand more clearly
the mutual relation of the novel pathological parame-
ters. Most studies only investigate one selected param-
eter. Thus, many studies do not elucidate if and how
invasive cribriform and intraductal carcinoma are dis-
tinguished. One biopsy study demonstrated that the
presence of invasive and/or intraductal carcinoma is
strongly associated with percentage Gleason pattern 4.
Among 370 ISUP grade 2 prostate cancers with <10%
Gleason pattern 4, CR/IDC occurred in 6% of men,
while this was 44% in patients with 25–50%.100 In
multivariate analysis, biopsy CR/IDC was an indepen-
dent parameter for postoperative biochemical recur-
rence in this study, while percentage grade 4 was not.
Another subject for future study is the detailed analy-
sis of individual Gleason 5 patterns, such as growth in
cords, single cells, solid fields and the presence of
comedonecrosis. We advocate that knowledge of the
clinical impact of the distinct Gleason 5 patterns and
elucidation of the mutual relations of these novel
pathological parameters will finally result in more
comprehensive and robust prostate cancer grading.
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